S-1: BIOLASE Eyes $24 Million in New Offering to Bolster Working Capital

BIOLASE, Inc. announces a best efforts offering of units and pre-funded units to raise capital for working capital and general corporate purposes.

Summary

• BIOLASE, Inc. is undertaking a best efforts offering consisting of units and pre-funded units.
• Each unit includes one share of common stock, one Class C warrant, and one Class D warrant.
• Pre-funded units are offered to purchasers who would otherwise exceed beneficial ownership limits, and each pre-funded unit includes one pre-funded warrant, one Class C warrant, and one Class D warrant.
• The assumed public offering price is $[] per unit, based on the closing price of BIOL's common stock on [], 2024.
• The company intends to use the net proceeds for working capital and general corporate purposes.
• The offering aims to raise up to $[] million, but the actual amount may be significantly less due to the best efforts nature of the offering.
• The Class C and Class D warrants will not be exercisable until stockholder approval is obtained.
• The Class C Warrants will expire five years from the date of Warrant Stockholder Approval and the Class D Warrants will expire one year from the date of Warrant Stockholder Approval.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the capital raise is a positive step, the company's financial struggles and risks associated with the offering temper the overall outlook.

Positives

• The offering aims to provide BIOLASE with additional working capital.
• Pre-funded units allow investors to participate without exceeding ownership limits.
• The company intends to use the net proceeds for working capital and general corporate purposes.

Negatives

• The offering is on a best efforts basis, so the company may not raise the full amount.
• The actual offering price may be at a discount to the current market price.
• The Class C and Class D warrants will not be exercisable until stockholder approval is obtained.
• The company has a history of net losses and substantial doubt about its ability to continue as a going concern.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• The market price of the company's common stock may be volatile.
• The company has a history of net losses and substantial doubt about its ability to continue as a going concern.
• Failure to meet Nasdaq's continued listing requirements could result in delisting of the common stock.

Future Outlook

The company believes that the net proceeds from this offering, together with its existing cash and cash equivalents, will meet its capital needs into [].

Industry Context

BIOLASE operates in the dental laser systems market, competing with companies offering similar technologies for various dental procedures. The announcement reflects the company's ongoing efforts to secure funding and maintain operations in a competitive environment.

Comparison to Industry Standards

• It is difficult to compare BIOLASE's results to industry standards without specific benchmarks for dental laser companies.
• Comparable companies in the medical device space include those focused on minimally invasive surgical technologies.
• However, direct comparisons are challenging due to variations in product portfolios, market focus, and financial structures.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Employees' job security is tied to the company's financial stability.
• Customers may be affected by the company's ability to invest in product development and support.
• Suppliers and creditors are exposed to the risk of the company's financial distress.

Next Steps

• The company intends to promptly seek Warrant Stockholder Approval.
• The company intends to attempt to take actions to restore our compliance with Nasdaqs listing requirements and intend to present a plan for compliance at the Panel hearing that is scheduled for June 2024.

Key Dates

Keywords

offering, units, pre-funded units, warrants, BIOLASE, capital raise, common stock, best efforts, stockholder approval, working capital